SA PRO
Free Account
Protagonist Therapeutics, Inc.PTGXNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 96% recommend buying.

Consensus Rating
Buy
23 analysts·High coverage
96%
Rating Distribution
Strong Buy
00%
Buy
2296%
Hold
14%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 30, 2026H.C. Wainwright
Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
Target:$117.00
+46.7%from $79.73
Jan 5, 2026Truist Financial
Protagonist Therapeutics price target raised to $110 from $88 at Truist
Target:$110.00
+26.2%from $87.18
Dec 17, 2025Barclays
Protagonist Therapeutics price target raised to $108 from $88 at Barclays
Target:$108.00
+18.0%from $91.54
Oct 28, 2025Truist Financial
Protagonist Therapeutics (PTGX) PT Raised to $88 at Truist Securities
Target:$88.00
+14.8%from $76.68
Oct 13, 2025Johnson Rice
Protagonist Therapeutics price target raised to $112 from $72 at BMO Capital
Target:$112.00
+28.7%from $87.00
Oct 7, 2025Johnson Rice
Protagonist Therapeutics price target raised to $74 from $62 at Clear Street
Target:$74.00
+13.0%from $65.47
Sep 16, 2025Barclays
Protagonist Therapeutics initiated with an Overweight at Barclays
Target:$72.00
+22.9%from $58.59
Mar 11, 2025Wedbush
Protagonist Therapeutics price target raised to $70 from $58 at Wedbush
Target:$70.00
+17.1%from $59.76
Mar 11, 2025Truist Financial
Protagonist Therapeutics price target raised to $76 from $60 at Truist
Target:$76.00
+27.2%from $59.76
Mar 3, 2025BTIG
Protagonist Therapeutics price target raised to $73 from $67 at BTIG
Target:$73.00
+89.6%from $38.50
Dec 5, 2024BMO Capital
BMO Capital Starts Protagonist Therapeutics (PTGX) at Outperform
Target:$62.00
+48.8%from $41.68
Nov 22, 2024Truist Financial
Truist Securities Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
Target:$60.00
+29.1%from $46.46
Sep 12, 2024H.C. Wainwright
Protagonist Therapeutics (PTGX) PT Raised to $50 at H.C. Wainwright
Target:$50.00
+10.9%from $45.08
Jun 17, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
Target:$38.00
+15.6%from $32.86

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance